Leukotriene antagonists
    3.
    发明公开
    Leukotriene antagonists 失效
    Leukotrienantagonisten。

    公开(公告)号:EP0403249A1

    公开(公告)日:1990-12-19

    申请号:EP90306438.4

    申请日:1990-06-13

    摘要: Compounds represented by the following structural formula (I):
    wherein q is O or 2;
    R₁ is (L) a -(CH₂) b -(T) c -M
    a is 0 or 1;
    b is 3 to 14;
    c is 0 or 1;
    L and T are independently oxygen or CH₂;
    M is C₁₋₄ alkyl, ethynyl, trifluoromethyl, isopropenyl, furanyl, thienyl, cyclohexyl or phenyl optionally monosubstituted with Br, Cl, CF₃, alkoxy, alkyl, methylthio, or trifluoromethylthio;
    Y is (CHX)(CH₂) p -Z wherein
    Z is COR₃, or tetrazolyl; in which
    R₃ is OH, NH₂, aryloxy, or C₁₋₆ alkoxy;
    p is 0, 1 or 2;
    X is OH, or alkoxy;
    R is -(CH₂) p -W;
    d is 0 to 6;
    W is phenyl substituted with B, C, or D;
    B is-(CH₂) p -V wherein p is 0 to 6 and V is COR₃, SO₃H, SO₂H, SO₂NH₂, COCH₂OH, CHOHCH₂OH, or tetrazolyl, with R₃ as defined above;
    C and D are independently selected from H, OH, F, Cl, Br, CF₃, alkyl, alkoxy, methylthio, trifluoromethylthio, NO₂, NH₂, NHalkyl, or CalkylCO-; or
    pharmaceutically acceptable salts thereof, can be used in the preparation of a medicament for the treatment of asthma.

    摘要翻译: 由以下结构式(I)表示的化合物:其中q为O或2; R 1是(L)a-(CH 2)b - (T)c-M a是0或1; b为3〜14; c为0或1; L和T独立地是氧或CH 2; M是C 1-6烷基,乙炔基,三氟甲基,异丙烯基,呋喃基,噻吩基,环己基或任选被Br,Cl,CF 3,烷氧基,烷基,甲硫基或三氟甲硫基单取代的苯基; Y是(CHX)(CH2)p -Z,其中Z是COR3或四唑基; 其中R 3是OH,NH 2,芳氧基或C 1-6烷氧基; p为0,1或2; X是OH或烷氧基; R是 - (CH 2)p -W; d为0〜6; W是被B,C或D取代的苯基; B为 - (CH 2)p -V,其中p为0至6,V为COR 3,SO 3 H,SO 2 H,SO 2 NH 2,COCH 2 OH,CHOHCH 2 OH或四唑基, C和D独立地选自H,OH,F,Cl,Br,CF 3,烷基,烷氧基,甲硫基,三氟甲硫基,NO 2,NH 2,NH烷基或C烷基CO-; 或其药学上可接受的盐可用于制备用于治疗哮喘的药物。